Results 231 to 240 of about 66,322 (262)

Tissue Inhibitors of Metalloproteinases in Cancer

2002
Our understanding of the biological function of tissue inhibitors of metalloproteinases (TIMP) has significantly evolved from an initial focus on the extracellular matrix (ECM) to a much broader function that includes a regulatory role on cell growth, survival and transformation. The bases for this larger role of TIMPs are several. 1.
openaire   +1 more source

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

Tissue Inhibitors of Metalloproteinases

2008
Liliana Guedez, Enrique Zudaire, William G. Stetler-Stevenson   +2 more
openaire   +1 more source

TISSUE INHIBITOR OF METALLOPROTEINASES

1986
T. E. Cawston, E. Mercer, C. Mooney, J. K. Wright   +3 more
openaire   +1 more source

Tissue Inhibitor of Metalloproteinase

2017
Marcello G. Masciantonio, Sean E. Gill
openaire   +1 more source

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly  

Tissue Inhibitors of Metalloproteinases

2012
openaire   +1 more source